Hospital

The use of intravenous immunoglobulin led to positive protective effects on osteoporosis.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

SMOs offer a range of services, including site selection, patient recruitment, data management, regulatory compliance, and quality assurance.

Propofol has a history of chronic shortage due to supply chain constraints.

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.

The drug is currently undergoing a phase 2 clinical trial for patient 12 years or older who are hospitalized with steroid-refractory acute graft-versus-host disease (aGVHD).

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.

Noticing indicators of IVIG non-responsiveness can lead to better outcomes among patients with Kawasaki disease as treatment is adjusted.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

The updates are based on nationwide reports of extreme pain during IUD insertion.

AI and other technologies, in conjunction with ASHP’s guidelines, can improve drug diversion monitoring and outcomes.

Investigators analyzed a series of disease-modifying therapies in a multi-decade trial.

The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.

The current outbreak has infected more than 14,000 people and spread to 13 different African countries.

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

The seroprotection rate of antibody titers was 100% against the 3 viruses, and geometric mean titer also increased from administration to day 43.